Results 51 to 60 of about 2,396,679 (391)

Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. [PDF]

open access: yes, 1994
Lipoproteins isolated from normal human plasma can bind and neutralize bacterial lipopolysaccharide (LPS) and may represent an important mechanism in host defense against gram-negative septic shock. Recent studies have shown that experimentally elevating
Kane, JP   +4 more
core   +1 more source

Fluorescence Enhancement of Fluorescein Isothiocyanate-Labeled Protein A Caused by Affinity Binding with Immunoglobulin G in Bovine Plasma

open access: yesSensors, 2009
Fluorescence enhancement of fluorescein isothiocyanate-labeled protein A (FITC-protein A) caused by the binding with immunoglobulin G (IgG) in bovine plasma was studied. FITC-protein A was immobilized onto a glass surface by covalent bonds.
Kiyotaka Sakai   +3 more
doaj   +1 more source

Prediction of drug-drug plasma protein binding interactions of resveratrol in combination with celecoxib and leflunomide by molecular docking combined with an ultrafiltration technique

open access: yesActa Pharmaceutica, 2020
The present study is aimed at computational prediction of the molecular interactions between resveratrol, celecoxib, leflunomide and human serum albumin (HSA) and then investigates the plasma protein binding of resveratrol combined with celecoxib or ...
Zhou Peng, Hua Fang
doaj   +1 more source

THE BINDING OF MYOGLOBIN BY PLASMA PROTEIN [PDF]

open access: yesThe Journal of Experimental Medicine, 1960
When added to dog plasma in vitro and in vivo, myoglobin was bound to plasma protein in a concentration which, maximally, averaged 21 ± 6 mg. per cent. Electrophoretically, bound myoglobin was separated from free myoglobin and migrated between alpha-2 and beta globulin.
openaire   +3 more sources

Complement activation and protein adsorption by carbon nanotubes [PDF]

open access: yes, 2006
As a first step to validate the use of carbon nanotubes as novel vaccine or drug delivery devices, their interaction with a part of the human immune system, complement, has been explored.
Flahaut, Emmanuel   +5 more
core   +2 more sources

Preclinical investigation of the pharmacokinetics, metabolism, and protein and red blood cell binding of DRDE-07: a prophylactic agent against sulphur mustard

open access: yesActa Pharmaceutica Sinica B, 2014
DRDE-07, a newly synthesized amifostine analog currently under clinical investigation in a phase I trial, is a potent antidote against sulfur mustard toxicity.
Pankaj Verma, Rajagopalan Vijayaraghavan
doaj   +1 more source

Design of Beta-2 Microglobulin Adsorbent Protein Nanoparticles

open access: yesBiomolecules, 2023
Beta-2 microglobulin (B2M) is an immune system protein that is found on the surface of all nucleated human cells. B2M is naturally shed from cell surfaces into the plasma, followed by renal excretion.
Justin E. Miller   +8 more
doaj   +1 more source

Binding of Novobiocin with Plasma Proteins

open access: yesExperimental Biology and Medicine, 1957
Summary1. Fraction studies with plasma from a dog treated with novobiocin showed that novobiocin is extensively bound to plasma albumin. 2.
Gunther W. Kuron   +4 more
openaire   +3 more sources

Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients [PDF]

open access: yes, 2018
BACKGROUND: Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM: To investigate the impact of direct-acting antiviral treatment on microbial translocation and T ...
Baroncelli, Silvia   +10 more
core   +1 more source

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

open access: yesFEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

Home - About - Disclaimer - Privacy